Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 76.00 | |
5 mg | In stock | $ 180.00 | |
10 mg | In stock | $ 266.00 | |
25 mg | In stock | $ 451.00 | |
50 mg | In stock | $ 663.00 | |
100 mg | In stock | $ 945.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 226.00 |
Description | Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively). |
Targets&IC50 | c-Met:32 nM, VEGFR2:30 nM |
In vitro | pamufetinib is ATP antagonism(Ki of 12 and 39 nM for rVEGFR2 and rMET, respectively). Like other known VEGFR or MET inhibitors, AS-115 strongly inhibits the kinase activity of VEGFR2 and MET and their signal-dependent cell growth. TAS-115 induces less damage in various normal cells than do other VEGFR inhibitors[1]. TAS-115 does not affect the growth of PC-9 or HCC827 cells at concentrations less than 10 μM; however, the combined use of TAS-115 with erlotinib reverses HGF-induced resistance in the cell lines in a concentration-dependent manner. VEGF production by cancer cells and endothelial proliferation inhibited by TAS-115[2]. |
In vivo | During the treatment period,pamufetinib (50 mg/kg/d) completely prevents tumor growth. In MET-amplified human cancer transplanted models,pamufetinib (200 mg/kg/d) induces a 48% regression from the initial tumor volume . ED50 of Tpamufetinib in this model is 8 mg/kg/d. Pamufetinib significantly prolongs survival of these mice when administered at doses of 50 or 200 mg/kg/d[1]. Pamufetinib inhibits angiogenesis in PC-9/HGF tumors in vivo. Moreover, the doublet erlotinib and pamufetinib successfully inhibit PC-9/HGF tumor growth and delay tumor regrowth associated with sustained tumor vasculature inhibition even after cessation of the treatment[2]. |
Synonyms | H2OL3Q4XRD, 4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide, TAS-115 |
Molecular Weight | 518.56 |
Formula | C27H23FN4O4S |
CAS No. | 1190836-34-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 13 mg/ml (25.07 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pamufetinib 1190836-34-0 Angiogenesis Tyrosine Kinase/Adaptors VEGFR c-Met/HGFR H2OL3Q4XRD 4-(2-Fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide Inhibitor TAS 115 inhibit TAS115 Vascular endothelial growth factor receptor TAS-115 inhibitor